New Amsterdam Sciences Announces Pre-IND Phase 2 Submission with FDA Coronavirus Treatment Acceleration Program for NAS150 Targeting the Omicron Variant and all variants of SARS-CoV-2

NAS Proposes Phase 2 Clinical Stage Agent Can Be an Effective Treatment and Adjuvant Therapeutic for COVID-19.   NAS150 Application Could Also Potentially Be Applied for COVID-19 Central Nervous System Conditions specifically those related to “Long Haul” conditions. Scottsdale, Arizona, December 3rd 2021 – New Amsterdam Sciences, a privately held Read more…

PR Distribution Services
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.